Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HR+/HER2-breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Not applicableUnknownNCT05814224
What this trial is testing

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

Who this might be right for
Hormone Receptor Positive Breast CarcinomaBreast NeoplasmsNeoplasms, Breast+4 more
Centro di Riferimento Oncologico - Aviano 164
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07197697
What this trial is testing

A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients

Who this might be right for
Breast Cancer
Anhui Provincial Cancer Hospital 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07005882
What this trial is testing

Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

Who this might be right for
Breast Cancer PatientsBreast Cancer Early Stage Breast Cancer (Stage 1-3)HR+/HER2- Breast Cancer+1 more
Azienda Ospedaliero-Universitaria Careggi 21
Large-scale testing (Phase 3)UnknownNCT05438810
What this trial is testing

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

Who this might be right for
Advanced Breast CancerFemale Breast Cancer
Ahon Pharmaceutical Co., Ltd. 312
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07757230
What this trial is testing

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 87
Large-scale testing (Phase 3)Study completedNCT02437318
What this trial is testing

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 572
Not applicableUnknownNCT05295043
What this trial is testing

Advanced Breast Cancer Study of CDK4/6 Inhibitor Combined With Endocrine Therapy Endocrine Therapy in HR+/HER2- Advanced Breast Cancer

Who this might be right for
Advanced HR+ HER2 Negative Breast Carcinoma
Tianjin Medical University Cancer Institute and Hospital 500
Post-approval studies (Phase 4)Ended earlyNCT04031885
What this trial is testing

Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 4
Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Testing effectiveness (Phase 2)Study completedNCT02648477
What this trial is testing

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Who this might be right for
Estrogen Receptor NegativeEstrogen Receptor PositiveHER2/Neu Negative+4 more
City of Hope Medical Center 30
Testing effectiveness (Phase 2)UnknownNCT04033172
What this trial is testing

Pyrotinib Plus Fulvestrant in Patients With HR+/HER2+ Metastatic Breast Cancer (Pyrotinib+Fulvestrant )

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Chinese Academy of Medical Sciences 40
Not applicableStudy completedNCT04916509
What this trial is testing

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

Who this might be right for
Breast Neoplasms
Pfizer 258
Large-scale testing (Phase 3)Not Yet RecruitingNCT07340658
What this trial is testing

Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced, Metastatic Breast Cancer
Rovi Pharmaceuticals Laboratories 300
Testing effectiveness (Phase 2)UnknownNCT05400993
What this trial is testing

Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC

Who this might be right for
Breast Cancer
Shengjing Hospital 59
Large-scale testing (Phase 3)Active Not RecruitingNCT06612814
What this trial is testing

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Zhimin Shao 307
Testing effectiveness (Phase 2)Looking for participantsNCT06227117
What this trial is testing

Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 120
Early research (Phase 1)UnknownNCT05504213
What this trial is testing

A Phase Ib Study of HS-10352 Plus Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 224
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07701941
What this trial is testing

Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor PositiveHER2-low or HER2-ultralowUnresectable or Metastatic Breast Cancer
Daiichi Sankyo 220
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07539753
What this trial is testing

Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in HR-Positive/HER2-Negative Advanced Breast Cancer With Brain Metastases

Who this might be right for
Breast CancerBrain MetastasesHR+/HER2- Breast Cancer
Nanfang Hospital, Southern Medical University 46
Next Page